Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Download PDF Copy

Aug 20 2010

Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

Quark is currently conducting a Phase II clinical trial of QPI-1002 for the prevention of acute kidney injury in patients undergoing cardiac surgery and for delayed graft function in kidney transplant patients. Based on the announcement issued by Quark on 18 August 2010, and under the terms of Silence's agreement with Quark, Silence anticipates that its future milestone payments from this program could potentially exceed $65 million.

Commenting on today's announcement, Phil Haworth, CEO of Silence, said: "We are delighted that Novartis has chosen to take this development option for QPI-1002. This serves as further validation of Silence's leading AtuRNAi technology and we look forward to receiving the significant milestones as the development of QPI-1002 continues."

SOURCE Silence Therapeutics plc

Posted in: Drug Trial News

Comments (0)

Download PDF Copy

Suggested Reading

New technology improves the efficiency of protein production in E. coli

Study highlights need to establish clinical practice guidelines for surgical patients receiving MOUDs

Clinical Frailty Scale can quickly predict mortality in patients with heart failure

Genomic mapping of resistance mutations in A. baumannii

Harnessing extracellular vesicles for targeted lung cancer treatment

Liver alterations associated with MASLD can directly affect the brain and behavior

Semaglutide can offer important heart benefits that go beyond weight loss

New study offers hope for patients with treatment-resistant focal epilepsy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.